Cell Therapy

Identifying CD31 protein expression in engineered tissue constructs serves as a vital indicator that a functional internal blood vessel network has begun to take shape. For patients grappling with catastrophic bone injuries or the aftermath of tumor removals, the quest for a permanent solution

The persistent search for a definitive treatment for Duchenne muscular dystrophy (DMD) has entered a sophisticated new era where regenerative medicine takes center stage against genetic muscle wasting. The FDA has recently cleared an expansion for a Phase 2 clinical trial that evaluates the safety

Before undergoing advanced cell therapy, Martha Durden-Scroggins experienced extreme physical fluctuations, oscillating between periods of stability and bouts of debilitating weakness. At seventy-one, her aggressive B-cell lymphoma had reached a critical juncture where conventional interventions no

Detecting minimal residual disease through high-sensitivity blood tests allows clinicians to identify high-risk patients who might benefit from immediate cellular therapy despite appearing to be in remission. This shift toward early intervention represents a departure from traditional

The pursuit of effective treatments for Duchenne muscular dystrophy has shifted focus toward managing cardiomyopathy, which currently stands as the most common cause of mortality for patients entering their second or third decade of life. Capricor Therapeutics recently faced significant headwinds

The medical landscape underwent a seismic shift recently when the Christie NHS Foundation Trust and the Royal Marsden launched the ZI-MA4-1 clinical trial, marking a pivotal moment for patients diagnosed with advanced solid tumors that have resisted standard treatments. For individuals like Tracy